相关临床试验
0
0 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
1943
暂无试验阶段数据
暂无试验数据
暂无试验数据
- The Foundation for Sarcoidosis Research (FSR) announced 13 inaugural clinical sites for its national FSR Clinical Data Registry, including Brigham and Women's Hospital, Stanford, Yale, and Duke University. - The longitudinal, multi-center registry aims to improve understanding of sarcoidosis through standardized data collection across geographically and ethnically diverse patient populations. - FSR spent two years developing the protocol with input from patients, caregivers, clinicians, and pharmaceutical partners to address the disease's multi-disciplinary nature. - The registry will complement the existing FSR-SARC Patient Registry, creating a comprehensive resource to advance diagnosis, biomarker discovery, therapy assessment, and patient outcomes.
- A clinical trial reveals that selinexor, an FDA-approved drug, effectively shrinks tumors in non-small cell lung cancer (NSCLC) patients with KRAS mutations. - The combination of selinexor and docetaxel controlled cancer in approximately 80% of cases, demonstrating effectiveness across various KRAS mutation types. - Researchers observed that selinexor exhibited anti-tumor effects independently before docetaxel administration, suggesting its potential as a standalone treatment. - This novel treatment offers hope for addressing the unmet clinical need for effective therapies targeting KRAS-mutated lung cancer, a challenging subset of the disease.
• Stereotactic ablative radiotherapy (SABR) is emerging as a valuable strategy for managing renal cell carcinoma (RCC), particularly in oligometastatic and oligoprogressive settings. • Studies indicate SABR can delay the need for systemic therapy in oligometastatic RCC, offering a less toxic and more cost-effective alternative to doublet immunotherapy regimens. • Research suggests SABR can extend the efficacy of existing systemic treatments in oligoprogressive RCC, potentially deferring the need for escalation to later-line therapies. • Ongoing trials are investigating SABR's role in treating primary RCC lesions and variant histologies, highlighting its versatility in advanced RCC management.
